Table 2 Comparison in clinical characteristics between patients with plaque regression and progression
| Â | Regression | Progression | P-value |
|---|---|---|---|
N=180 | N=28 | ||
Age (yrs) | 62.4 ± 10.6 | 65.8 ± 13.6 | 0.1 |
Male | 142 (78.9) | 24 (85.7) | 0.4 |
BMI (kg/m2) | 24.3 ± 3.5 | 23.6 ± 2.5 | 0.2 |
Diabetes mellitus | 48 (26.7) | 14 (50.0) | 0.016 |
Hypertension | 107 (59.4) | 20 (71.4) | 0.2 |
Smoking | 85 (47.2) | 11 (39.3) | 0.4 |
History of prior PCI | 12 (6.7) | 1 (3.6) | 0.5 |
Type of ACS | Â | Â | 0.3 |
STEMI | 113 (62.8) | 21 (75.0) | |
NSTEMI | 26 (14.4) | 4 (14.3) | |
UAP | 41 (22.8) | 3 (10.7) | |
Culprit Vessel | Â | Â | 0.1 |
RCA | 56 (31.1) | 14 (50.0) | |
LAD | 99 (55.0) | 13 (46.4) | |
LCX | 24 (13.3) | 1 (3.6) | |
LMT | 1 (0.6) | 0 (0) | |
Type of stent | Â | Â | 0.6 |
BMS | 120 (66.7) | 19 (67.9) | Â |
DES | 57 (31.7) | 9 (32.1) | Â |
Other than Stent (POBA) | 3 (1.7) | 0 (0) | Â |
Analysis Segment | Â | Â | 0.6 |
Proximal to target site | 124 (68.9) | 18 (64.3) | Â |
Distal to target site | 56 (31.1) | 10 (35.7) | Â |
Use of pitavastatin | 96 (53.3) | 14 (50.0) | 0.7 |